Mild cognitive impairment in patients with Parkinson's disease is associated with increased cortical degeneration

Alexandru Hanganu1, Christophe Bedetti, Thomas Jubault

  • 1Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montréal, Quebec, Canada.

Insights

Mild cognitive impairment (MCI) in Parkinson's disease (PD) is linked to greater cortical changes. These changes, particularly in brain regions like the occipital lobe, may predict dementia risk in PD patients.

Area of Science:

  • Neuroscience
  • Neurology
  • Radiology

Background:

  • Mild cognitive impairment (MCI) is an early symptom in Parkinson's disease (PD) and elevates dementia risk.
  • Identifying cortical alterations in PD-MCI can aid in predicting dementia progression.

Purpose of the Study:

  • To investigate cortical changes (thickness and surface area) in Parkinson's disease patients with and without mild cognitive impairment (MCI).
  • To correlate these cortical changes with disease duration.

Main Methods:

  • Anatomic magnetic resonance imaging (MRI) was used for corticometry analysis.
  • 37 PD patients (18 with MCI, 19 without MCI) and 16 controls were studied.
  • Cortical thickness and surface area were measured and correlated with disease duration.

Main Results:

  • PD patients with MCI showed greater atrophy and surface area changes in occipital, temporal, and frontal cortices compared to controls.
  • PD patients without MCI exhibited less pronounced, unilateral changes in the occipital and frontal lobes.
  • The PD-MCI group had significantly increased surface area in the occipital lobe, temporal lobe, and postcentral gyrus compared to the PD non-MCI group.
  • Cortical thickness negatively correlated with disease duration in the PD-MCI group but not in the PD non-MCI group.

Conclusions:

  • Mild cognitive impairment in Parkinson's disease is associated with more extensive cortical degeneration.
  • These findings suggest that MCI exacerbates cortical changes in PD, potentially indicating a higher risk for dementia.

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...